Marburg Virus Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Marburg virus outbreak in West Africa
Curr Drug Targets. 2023 Feb 13. doi: 10.2174/1389450124666230213154319. Online ahead of print.NO ABSTRACTPMID:36788691 | DOI:10.2174/1389450124666230213154319 (Source: Current Drug Targets)
Source: Current Drug Targets - February 15, 2023 Category: Drugs & Pharmacology Authors: Sarmili Sahoo Raj Kumar Narang Amandeep Singh Source Type: research

Marburg Vaccine Safe, Immunogenic in Phase 1 Trial
An investigational Marburg virus vaccine was well-tolerated and generated an enduring immune response after a single dose, according to the results of a phase 1 clinical trial. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - February 15, 2023 Category: General Medicine Source Type: research

Marburg virus outbreak: researchers race to test vaccines
Nature, Published online: 15 February 2023; doi:10.1038/d41586-023-00468-5Control measures such as quarantine could end the outbreak in Equatorial Guinea quickly — good news for inhabitants but a mixed blessing for clinical trials. (Source: Nature AOP)
Source: Nature AOP - February 15, 2023 Category: Research Authors: Ewen Callaway Source Type: research

Chaperoning the Driver of Filovirus Egress to a Dead End
Autophagy. 2023 Feb 10. doi: 10.1080/15548627.2023.2178781. Online ahead of print.ABSTRACTEbola virus (EBOV) and Marburg virus (MARV) are zoonotic, virulent pathogens that cause sporadic and global outbreaks of severe hemorrhagic fever. Re-emergence of these filoviruses remains a global public health threat, highlighting the need for novel countermeasures to control and treat future disease outbreaks. The EBOV VP40 matrix protein drives virion assembly and egress. We recently reported that BAG3 and HSPA/HSP70, two central components of chaperone-assisted selective autophagy (CASA), target VP40 for autophagic sequestration ...
Source: Autophagy - February 10, 2023 Category: Cytology Authors: Jingjing Liang Marija A Djurkovic Olena Shtanko Ronald N Harty Source Type: research

Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features —A case series
ConclusionWe propose that Tumefactive lesions larger than 4 cm are termed “Giant demyelinating lesions” (GDLs) not only on the basis of size, but a rapid and fulminant demyelinating presentation leading to acute, severe neurological disability that is, nonetheless, responsive to immunotherapy. Further clinical studies are required to ratify this proposed phenotype, establish the immunological profile and best treatment for such patients. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - February 3, 2023 Category: Neurology Source Type: research

Influence of Fibrinogen Concentrate on Neonatal Clot Structure When Administered Ex Vivo After Cardiopulmonary Bypass
CONCLUSIONS: Our results show that clots formed ex vivo with clinically relevant doses of FC (0.9 mg/mL) display similar structural and degradation characteristics compared to the in vivo transfusion of cryoprecipitate. These findings suggest that FC is effective in restoring structural fibrin clot properties after CPB. Future studies after the administration of FC in vivo are needed to validate this hypothesis.PMID:36727748 | DOI:10.1213/ANE.0000000000006357 (Source: Anesthesia and Analgesia)
Source: Anesthesia and Analgesia - February 2, 2023 Category: Anesthesiology Authors: Nina Moiseiwitsch Kimberly A Nellenbach Laura A Downey David Boorman Ashley C Brown Nina A Guzzetta Source Type: research